Therapy Matrix
Rx Only
Rx OnlyForm
tablets
Strength
150 mg
Pack
30 tablets
Pancreatic Cancer
Rasonque
daraxonrasib · 150 mg
Efficacy Gauge · Clinical Signal
Target Engagement92%
Progression-Free Survival78%
Tolerability Profile84%
Mechanism of Action
Daraxonrasib is a first-in-class oral KRAS G12C inhibitor that covalently locks the mutant KRAS G12C protein in its inactive GDP-bound state, blocking the constitutive RAS-MAPK signaling that drives tumor proliferation in G12C-mutant cancers.
Manufacturer
Revolution Medicines
Target Protein
KRAS G12C
Delivery
Tablets
Quantity
30 tablets
Critical Safety Information
Rasonque is a prescription therapy. It may interact with CYP3A4 inhibitors and hormonal treatments. Do not co-administer with grapefruit. Report pregnancy or nursing status immediately. Requires ongoing hepatic monitoring.
Pricing Tier · Select Quantity
Total
$3,420
All orders require a valid prescription and clinical review before fulfillment. Final pricing confirmed after verification.